by Inga Peters, Katja Derlin, Matti Joonas Peperhove, Bennet Hensen, Stefanie Pertschy, Mathias Wolters, Christoph-Alexander Joachim von Klot, Frank Wacker, Susanne Hellms
Abstract:
Aim: To share our experience after 28 cryoablation treatments for prostate cancer (PCa) with histopathology, clinical data and MRI as the follow-up methods. Methods: Clinical follow-up comprised prostate-specific antigen (PSA)-measurements, PSA-density and quality of life-parameters. multi-parametric (mp)MRI pre- and post-cryoablation were retrospectively re-analyzed in 23 cases using Likert scores. Follow-up-histopathology was performed via MRI/ultrasound fusion-guided and/or systematic biopsy. Receiver operating characteristic curve analysis was performed. Results: 17 PCa (61\%) were diagnosed within 12-month post-cryotherapy (infield and out-of-field disease). PSA levels and PSA density were not significantly different between patients with or without PCa recurrence. mpMRI can characterize the decrease in prostate volume and necrosis. Area under the curve for the detection of PCa was 81\% (global Likert scores), 74-87\% (T2), 78\% (diffusion weighted imaging) and 57-78\% (dynamic contrast enhanced imaging; Youden-selected cutoff ≥3). Conclusion: Besides histopathological evaluation and control biopsy, MRI might have the potential to accurately detect PCa after cryotherapy. Clinical data and interdisciplinary communication are required for efficient monitoring after cryoablation treatments for PCa.
Reference:
First experiences and results after cryoablation of prostate cancer with histopathological evaluation and imaging-based follow-up. (Inga Peters, Katja Derlin, Matti Joonas Peperhove, Bennet Hensen, Stefanie Pertschy, Mathias Wolters, Christoph-Alexander Joachim von Klot, Frank Wacker, Susanne Hellms), In Future oncology (London, England), volume 18, 2022.
Bibtex Entry:
@article{peters_first_2022,
title = {First experiences and results after cryoablation of prostate cancer with histopathological evaluation and imaging-based follow-up.},
volume = {18},
issn = {1744-8301 1479-6694},
doi = {10.2217/fon-2021-1146},
abstract = {Aim: To share our experience after 28 cryoablation treatments for prostate cancer (PCa) with histopathology, clinical data and MRI as the follow-up methods. Methods: Clinical follow-up comprised prostate-specific antigen (PSA)-measurements, PSA-density and quality of life-parameters. multi-parametric (mp)MRI pre- and post-cryoablation were retrospectively re-analyzed in 23 cases using Likert scores. Follow-up-histopathology was performed via MRI/ultrasound fusion-guided and/or systematic biopsy. Receiver operating characteristic curve analysis was performed. Results: 17 PCa (61\%) were diagnosed within 12-month post-cryotherapy (infield and out-of-field disease). PSA levels and PSA density were not significantly different between patients with or without PCa recurrence. mpMRI can characterize the decrease in prostate volume and necrosis. Area under the curve for the detection of PCa was 81\% (global Likert scores), 74-87\% (T2), 78\% (diffusion weighted imaging) and 57-78\% (dynamic contrast enhanced imaging; Youden-selected cutoff ≥3). Conclusion: Besides histopathological evaluation and control biopsy, MRI might have the potential to accurately detect PCa after cryotherapy. Clinical data and interdisciplinary communication are required for efficient monitoring after cryoablation treatments for PCa.},
language = {eng},
number = {14},
journal = {Future oncology (London, England)},
author = {Peters, Inga and Derlin, Katja and Peperhove, Matti Joonas and Hensen, Bennet and Pertschy, Stefanie and Wolters, Mathias and von Klot, Christoph-Alexander Joachim and Wacker, Frank and Hellms, Susanne},
month = may,
year = {2022},
pmid = {35255716},
keywords = {*Cryosurgery/adverse effects, *Prostatic Neoplasms/diagnostic imaging/pathology/surgery, cryoablation, focal therapy, follow-up, Follow-Up Studies, Humans, Image-Guided Biopsy/methods, Magnetic Resonance Imaging/methods, Male, multiparametric MRI, PI-RADS, Prostate cancer, Prostate-Specific Antigen, Quality of Life, Retrospective Studies},
pages = {1705--1716}
}